Several recent studies suggest that selective CB2 receptor agonists may represent a valid pharmacological approach in the treatment of various diseases due to the absence of relevant psychoactive side effect. In this study, we synthesized and tested a series of new quinoline-2(1H)-one- and 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine derivatives characterized by a 4-methylcyclohexylamido substituent in position 3 of the heterocyclic nucleus with high CB2 receptor affinity and selectivity. Two compounds showing the best binding and selectivity profile behaved as a full agonist and a partial agonist at the CB2 receptor and induced a concentration-dependent decrease of cell viability on LNCaP, a prostatic cancer cell line expressing CB2 receptor. Moreover considering that the CB2 receptor is mainly expressed in cells and organs of the immune system, the same compounds were studied for their potential immune-modulatory and anti-inflammatory effects in activated lymphocytes isolated from healthy controls and multiple sclerosis (MS) patients.

New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity

MANERA, CLEMENTINA
Co-primo
;
CARPI, SARA;FOGLI, STEFANO;BERTINI, SIMONE;SACCOMANNI, GIUSEPPE;NIERI, PAOLA;MACCHIA, MARCO
Penultimo
;
2015-01-01

Abstract

Several recent studies suggest that selective CB2 receptor agonists may represent a valid pharmacological approach in the treatment of various diseases due to the absence of relevant psychoactive side effect. In this study, we synthesized and tested a series of new quinoline-2(1H)-one- and 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine derivatives characterized by a 4-methylcyclohexylamido substituent in position 3 of the heterocyclic nucleus with high CB2 receptor affinity and selectivity. Two compounds showing the best binding and selectivity profile behaved as a full agonist and a partial agonist at the CB2 receptor and induced a concentration-dependent decrease of cell viability on LNCaP, a prostatic cancer cell line expressing CB2 receptor. Moreover considering that the CB2 receptor is mainly expressed in cells and organs of the immune system, the same compounds were studied for their potential immune-modulatory and anti-inflammatory effects in activated lymphocytes isolated from healthy controls and multiple sclerosis (MS) patients.
2015
Manera, Clementina; Malfitano, Anna Maria; Parkkari, Teija; Lucchesi, Valentina; Carpi, Sara; Fogli, Stefano; Bertini, Simone; Laezza, Chiara; Ligresti, Alessia; Saccomanni, Giuseppe; Savinainen, Juha R; Ciaglia, Elena; Pisanti, Simona; Gazzerro, Patrizia; Di Marzo, Vincenzo; Nieri, Paola; Macchia, Marco; Bifulco, Maurizio
File in questo prodotto:
File Dimensione Formato  
2015 Manera and Bifulco European Journal of Medicinal Chemistry.pdf

solo utenti autorizzati

Descrizione: Articolo definitivo
Tipologia: Versione finale editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 839.94 kB
Formato Adobe PDF
839.94 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
manuscriptF.doc

accesso aperto

Tipologia: Documento in Pre-print
Licenza: Creative commons
Dimensione 579 kB
Formato Microsoft Word
579 kB Microsoft Word Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/750832
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 36
social impact